Skip to main content
2023 ACCP Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Kefeng Sun, PhD

Clinical Pharmacology
Takeda Pharmaceutical Co Ltd

Kefeng Sun, Ph.D. is currently an Associate Scientific Director at Takeda. Kefeng attained his Ph.D. in Pharmaceutical Sciences from the University of Michigan College of Pharmacy in 2013. He first worked on small molecular drug metabolism and pharmacokinetics (DMPK) at Eli Lilly & Company, then joined Shire (now part of Takeda) in late 2017. Kefeng’s roles at Shire / Takeda evolved from program leaders in DMPK, quantitative systems pharmacology (QSP) to quantitative clinical pharmacology (QCP) over the past 5 years. Kefeng’s quantitative analyses and leadership have directly enabled one new drug approval, as well as multiple first-in-human study clearances. Currently, his main research interest is utilizing mechanistic and pharmacometric modeling & simulation to enable translational and regulatory approaches for both traditional and novel therapeutic modalities.
Kefeng is experienced in translational and clinical aspects of gene therapy. He has published multiple peer-reviewed manuscripts and given multiple public lectures on quantitative analysis and regulatory pathways of AAV gene therapy. Kefeng is the co-founder of ASCPT Cell, Gene, Regenerative and Nucleic Acid Community, which champions pan-industry efforts on quantitative aspects of new modalities.

Presentation(s):